Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02763605
Other study ID # 201312046RINB
Secondary ID
Status Recruiting
Phase N/A
First received April 12, 2016
Last updated May 5, 2016
Start date January 2014
Est. completion date July 2016

Study information

Verified date May 2016
Source National Taiwan University Hospital
Contact Chia-ju Lu, MD
Phone +886223123456
Email lcjjulie@gmail.com
Is FDA regulated No
Health authority Taiwan: Ministry of Health and Welfare
Study type Observational

Clinical Trial Summary

Acanthamoebic keratitis is an important corneal disease which may cause severe complication. The difficulty in diagnosis, the difficulty in treatment, and the long treatment process are factors leading to the poor prognosis of these patients. In this retrospective study, the investigators try to analyze the tissue proven Acanthamoebic keratitis diagnosed in our hospital. The investigators will focus on the in vivo confocal microscopic results, the medical history and the medical/surgical treatment outcome. The investigators will collect the tissue proven cases according to the data provided by laboratory diagnosis department and pathological department. The in vivo confocal microscopic results will be collected and analyzed. The investigators will also look through the photography of the external eyes from data stored in PAC system. The medical history and treatment outcome will be studied from clinical chart review. From this study, the investigators aimed to find out a easy way of diagnosing Acanthamoebic keratitis from in vivo confocal microscopy, and find out a better way for treatment.


Description:

Acanthamoeba keratitis (AK), caused by a pathogenic amoeba, is a sight-threatening corneal infection with severe pain, epithelial defect, epithelial haze, pseudodendrites, and, most characteristically, radial keratoneuritis. The corneal infection of AK was first recognized in the mid 1970s. Since then, a growing number of AK cases were diagnosed, mainly resulting from improper use of soft contact lenses.

Clinical diagnosis of AL is difficult, especially in the early phases of the disease, and it often is misdiagnosed and treated as a herpes simplex infection. It was reported a diagnostic delay of more than 18 days between onset of symptoms and start of anti- amoebic treatment results in a poor disease progress. While definitive diagnosis is made by confirmation of Acanthamoeba cysts or trophozoites in corneal lesions by staining, corneal biopsy, or tissue culturing.

In vivo confocal microscopy was considered useful in the rapid diagnosis of AK. The Acanthamoeba cysts were observed almost exclusively in the epithelial cell layer as highly reflective, round or stellate, high-contrast particles with a diameter of 10 to 20 μm. It was suggested that invasion of Acanthamoeba cysts into Bowman's layer may be a useful predictor for a persistent clinical course. The trophozoites are pear-shaped or irregularly wedge-shaped structures, some surrounded by a brilliant halo some exhibiting fine pseudopodia-like extensions, with mean size of 30.2 µm (range 19.2-55.6μm). It was reported to present in cornea stroma. Highly reflective activated keratocytes forming a honeycomb pattern change was reported to be present around the keratoneuritis. In addition, infiltration of inflammatory cells, possibly polymorphonuclear cells, was observed along with the keratocytes in cases of AK. However, the in vivo confocal microscopic findings in patients with AK is still limited. Some clinical findings may not be correlated with the reports published before.

John K.G. et al recommended clinical treatment toward Acanthamoeba keratitis using Diamidine and Biguanide which are the only two proofed Acanthamoeba cysticidal medication, while Metronidazole is effective in vivo but not in vitro. Topical steroid was considered rather controversial but important and beneficial. It was recommended to use a minimum of 2 weeks of Biguanide prior to the use of topical steroid for inflammation control. When Acanthamoeba keratitis was diagnosed early in the disease course, topical steroid can be spared for the immediate using Diamidine and Biguanide to kill pathogen. In a United Kingdom multicenter study of 218 patients, the average duration of medical therapy was 6 months (range, 0.5 to 29 months). In 2011, a little over half of respondents using corticosteroids in the treatment of Acanthamoeba keratitis. Surgical managements including epithelial debridement, cryotherapy and corneal graft surgery may itself be therapeutic if performed early and promote penetration. Therefore, when Acanthamoeba keratitis was suspected, a long-term and immediate medical treatment may be needed ,and the use of topical steroid toward Acanthamoeba keratitis is still worth investigating.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 10 Years to 90 Years
Eligibility Inclusion Criteria:

- presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016

- suspecting Acanthamoeba Keratitis by the ophthalmologist

- drug treatment as Acanthamoeba Keratitis successed

- tissue proved to be Acanthamoeba Keratitis

- referred from the other hospital with the diagnose of Acanthamoeba Keratitis

Exclusion Criteria

- patients suspect corneal Acanthamoeba Keratitis from Jun. 1st, 2003 to dec. 30th , 2013, but without in vivo confocal data, or complete chart records.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Other:
no intervention


Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (13)

Claerhout I, Goegebuer A, Van Den Broecke C, Kestelyn P. Delay in diagnosis and outcome of Acanthamoeba keratitis. Graefes Arch Clin Exp Ophthalmol. 2004 Aug;242(8):648-53. — View Citation

Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol. 2009 Oct;148(4):487-499.e2. doi: 10.1016/j.ajo.2009.06.009. Epub 2009 Aug 5. Review. — View Citation

Mathers WD, Sutphin JE, Folberg R, Meier PA, Wenzel RP, Elgin RG. Outbreak of keratitis presumed to be caused by Acanthamoeba. Am J Ophthalmol. 1996 Feb;121(2):129-42. — View Citation

Matsumoto Y, Dogru M, Sato EA, Katono Y, Uchino Y, Shimmura S, Tsubota K. The application of in vivo confocal scanning laser microscopy in the management of Acanthamoeba keratitis. Mol Vis. 2007 Jul 25;13:1319-26. — View Citation

Naginton J, Watson PG, Playfair TJ, McGill J, Jones BR, Steele AD. Amoebic infection of the eye. Lancet. 1974 Dec 28;2(7896):1537-40. — View Citation

Oldenburg CE, Acharya NR, Tu EY, Zegans ME, Mannis MJ, Gaynor BD, Whitcher JP, Lietman TM, Keenan JD. Practice patterns and opinions in the treatment of acanthamoeba keratitis. Cornea. 2011 Dec;30(12):1363-8. doi: 10.1097/ICO.0b013e31820f7763. — View Citation

Parmar DN, Awwad ST, Petroll WM, Bowman RW, McCulley JP, Cavanagh HD. Tandem scanning confocal corneal microscopy in the diagnosis of suspected acanthamoeba keratitis. Ophthalmology. 2006 Apr;113(4):538-47. — View Citation

Pfister DR, Cameron JD, Krachmer JH, Holland EJ. Confocal microscopy findings of Acanthamoeba keratitis. Am J Ophthalmol. 1996 Feb;121(2):119-28. — View Citation

Radford CF, Lehmann OJ, Dart JK. Acanthamoeba keratitis: multicentre survey in England 1992-6. National Acanthamoeba Keratitis Study Group. Br J Ophthalmol. 1998 Dec;82(12):1387-92. — View Citation

Rezaei Kanavi M, Naghshgar N, Javadi MA, Sadat Hashemi M. Various confocal scan features of cysts and trophozoites in cases with Acanthamoeba keratitis. Eur J Ophthalmol. 2012;22 Suppl 7:S46-50. doi: 10.5301/ejo.5000139. — View Citation

Shiraishi A, Uno T, Oka N, Hara Y, Yamaguchi M, Ohashi Y. In vivo and in vitro laser confocal microscopy to diagnose acanthamoeba keratitis. Cornea. 2010 Aug;29(8):861-5. doi: 10.1097/ICO.0b013e3181ca36b6. — View Citation

Winchester K, Mathers WD, Sutphin JE, Daley TE. Diagnosis of Acanthamoeba keratitis in vivo with confocal microscopy. Cornea. 1995 Jan;14(1):10-7. — View Citation

Yokogawa H, Kobayashi A, Yamazaki N, Ishibashi Y, Oikawa Y, Tokoro M, Sugiyama K. Bowman's layer encystment in cases of persistent Acanthamoeba keratitis. Clin Ophthalmol. 2012;6:1245-51. doi: 10.2147/OPTH.S34695. Epub 2012 Aug 2. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with typical image finding under an in vivo confocal microscope (Confoscan 3.4.1; Nidek Technologies, Padova, Italy) through study completion, an average of about 10 year microscope diagnosis and disease progress prediction of patients with Acanthamoe No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02506257 - Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects Phase 1
Enrolling by invitation NCT03461978 - Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures N/A
Active, not recruiting NCT03484507 - Parasitic Ulcer Treatment Trial Pilot Phase 2
Recruiting NCT05110001 - Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction Phase 3
Completed NCT03274895 - Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis Phase 3
Not yet recruiting NCT06332703 - Acanthamoeba and Artificial Intelligence
Not yet recruiting NCT06213649 - Parasitic Ulcer Treatment Trial Phase 3